Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

Author： Hong David S.   Garrido-Laguna Ignacio   Ekmekcioglu Suhendan   Falchook Gerald S.   Naing Aung   Wheler Jennifer J.   Fu Siqing   Moulder Stacy L.   Piha-Paul Sarina   Tsimberidou Apostolia M.   Wen YueJin   Culotta Kirk S.   Anderes Kenna   Davis Darren W.   Liu Wen   George Goldy C.   Camacho Luis H.   Percy Ivy Susan   Kurzrock Razelle  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|14|2164-2173

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.14, 2014-07, pp. : 2164-2173

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study

By LoRusso Patricia   Krishnamurthi Smitha   Youssoufian Hagop   Hall Nancy   Fox Floyd   Dontabhaktuni Aruna   Grebennik Dmitri   Remick Scot  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 303-311

Springer Publishing Company

Access to resources Recommend Favorite

Phase I Clinical Trial of Exherin (ADH-1) in Patients with Advanced Solid Tumors

By  

Current Clinical Pharmacology, Vol. 8, Iss. 1, 2013-02 ,pp. : 81-88

Bentham Science Publishers

Access to resources Recommend Favorite

Phase I Trial of the Polyamine Analog N1,N14-Diethylhomospermine (DEHSPM) in Patients with Advanced Solid Tumors

By Wilding George   King David   Tutsch Kendra   Pomplun Marcia   Feierabend Chris   Alberti Dona   Arzoomanian Rhoda  

Investigational New Drugs, Vol. 22, Iss. 2, 2004-04 ,pp. : 131-138

Springer Publishing Company

Access to resources Recommend Favorite

Phase 1 trial of Anvirzel™ in patients with refractory solid tumors

By Mekhail Tarek   Kaur Hanspreet   Ganapathi Ram   Budd G.   Elson Paul   Bukowski Ronald  

Investigational New Drugs, Vol. 24, Iss. 5, 2006-09 ,pp. : 423-427

Springer Publishing Company

Access to resources Recommend Favorite

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

By Samol Jens  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1493-1500

Springer Publishing Company

Access to resources Recommend Favorite